Clarius Group, LLC Gilead Sciences, Inc. Transaction History

Clarius Group, LLC

$1.4 Billion
Q3 2024

A detailed history of Clarius Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 7,023 shares of GILD stock, worth $650,189. This represents 0.04% of its overall portfolio holdings.

Number of Shares

7,023

Previous 7,301 3.81%

Holding current value

$650,189

Previous $500,000 17.6%

% of portfolio

0.04%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$66.59 - $83.99 $18,512 - $23,349	-278 Reduced 3.81%	7,023 $588,000
Q2 2024 Jul 11, 2024	SELL	$63.15 - $72.88 $13,956 - $16,106	-221 Reduced 2.94%	7,301 $500,000
Q1 2024 Apr 17, 2024	SELL	$71.58 - $87.29 $165,994 - $202,425	-2,319 Reduced 23.56%	7,522 $550,000
Q4 2023 Jan 29, 2024	BUY	$73.27 - $83.09 $26,377 - $29,912	360 Added 3.8%	9,841 $797,000
Q3 2023 Oct 19, 2023	SELL	$73.94 - $80.67 $263,152 - $287,104	-3,559 Reduced 27.29%	9,481 $710,000
Q2 2023 Aug 09, 2023	BUY	$76.01 - $86.7 $2,584 - $2,947	34 Added 0.26%	13,040 $1 Million
Q1 2023 Apr 17, 2023	BUY	$77.31 - $88.08 $84,886 - $96,711	1,098 Added 9.22%	13,006 $1.08 Million
Q4 2022 Jan 25, 2023	BUY	$62.32 - $89.47 $57,521 - $82,580	923 Added 8.4%	11,908 $1.02 Million
Q3 2022 Oct 24, 2022	BUY	$59.54 - $68.01 $277,694 - $317,198	4,664 Added 73.79%	10,985 $678,000
Q2 2022 Aug 10, 2022	SELL	$57.72 - $65.01 $235,151 - $264,850	-4,074 Reduced 39.19%	6,321 $391,000
Q4 2021 Feb 02, 2022	BUY	$64.88 - $73.64 $48,465 - $55,009	747 Added 7.74%	10,395 $755,000
Q3 2021 Oct 18, 2021	BUY	$67.69 - $73.03 $23,285 - $25,122	344 Added 3.7%	9,648 $674,000
Q2 2021 Aug 06, 2021	BUY	$63.47 - $69.35 $1,269 - $1,387	20 Added 0.22%	9,304 $641,000
Q1 2021 Apr 27, 2021	BUY	$60.0 - $68.46 $214,380 - $244,607	3,573 Added 62.56%	9,284 $600,000
Q4 2020 Jan 15, 2021	SELL	$56.65 - $64.55 $52,004 - $59,256	-918 Reduced 13.85%	5,711 $333,000
Q3 2020 Oct 09, 2020	SELL	$62.1 - $78.08 $258,460 - $324,968	-4,162 Reduced 38.57%	6,629 $419,000
Q2 2020 Jul 08, 2020	BUY	$72.34 - $84.0 $111,258 - $129,192	1,538 Added 16.62%	10,791 $830,000
Q1 2020 Apr 24, 2020	BUY	$62.63 - $80.22 $73,339 - $93,937	1,171 Added 14.49%	9,253 $692,000
Q4 2019 Jan 22, 2020	BUY	$61.62 - $67.78 $35,246 - $38,770	572 Added 7.62%	8,082 $518,000
Q3 2019 Oct 23, 2019	BUY	$62.51 - $69.0 $71,261 - $78,660	1,140 Added 17.9%	7,510 $476,000
Q2 2019 Aug 02, 2019	BUY	$61.87 - $69.38 $76,347 - $85,614	1,234 Added 24.03%	6,370 $430,000
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $106,488 - $119,295	1,703 Added 49.61%	5,136 $334,000
Q4 2018 Feb 11, 2019	BUY	$60.54 - $79.0 $207,833 - $271,207	3,433 New	3,433 $215,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.

Account

Clarius Group, LLC Gilead Sciences, Inc. Transaction History